新型镇静药物瑞马唑仑的临床研究进展

Clinical research progress of remimazolam——a novel sedative drug

瑞马唑仑是一种新型超短效苯二氮类镇静药,作用于GABA_(A)受体,经羧酸酯酶代谢而不依赖于器官代谢,代谢产物无活性,相较于目前临床常应用的镇静药物咪达唑仑、丙泊酚、右美托咪定等,具有起效快、代谢快、无蓄积、不良反应小、可控性强等优势。现综述瑞马唑仑在麻醉诱导、程序性镇静以及静脉麻醉、重症患者镇静等领域的临床研究进展,现有证据表明瑞马唑仑有望成为ICU重症患者镇静的理想药物。

Remimazolam is a new⁃type ultra⁃short⁃acting benzodiazepine sedative/anesthetic agent,acting on GABA_(A) receptor.It is metabolized by carboxylesterases and independent from organ metabolism.The metabolites are inactive.Comparing with other sedative agents such as midazolamm,propofol,and dexmedetomidine,remimazolam has fast onset time,short duration of action,less accumulation and good safety profile and is easily monitored.This article reviews clinical research progress of this drug in anesthesia induction,procedural sedation,intravenous anesthesia,and sedation of critically ill patients.The existing evidence shows that remimazolam is expected to be an ideal sedative agent for critically ill patients in intensive care unit(ICU).